ASC30 vs VCT220

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

ASC30

Developed by Ascletis Pharma

Phase 3 in Obesitysmall molecule
Partial signal

NCT07002905 · Phase 2 · completed

The study randomly assigned 125 participants and used quadruple blinding with placebo control across seven cohorts. Its primary endpoint was percent change in body weight at Week 13, but the registry has not posted whether this endpoint was met.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: July 2028 · NCT07743463 (registry estimate)

Reported efficacy

Percent change in body weight from Baseline up to Week 13 (Baseline and Week 13): Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo (met)

Result source: NCT07002905

VCT220

Developed by Ji Xing Pharmaceuticals (CORXEL) and partners

Phase 3 in Obesitysmall molecule
Partial signal

NCT06939296 · Phase 3 · completed

This was a randomized, double-blind Phase 3 trial with 840 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-05-18. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: March 2027 · NCT07652047 (registry estimate)

Reported efficacy

Percentage change from baseline in body weight (From baseline to week 34); The proportion of subjects with a body weight reduction ≥5% from baseline (From baseline to week 34): Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18). (met)

Result source: NCT06939296

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointASC30VCT220
Body weight, % change—Trial running · NCT07743463—Not posted · NCT06939296
Weight loss of 5% or more—Trial running · NCT07743463—Not posted · NCT06939296
Weight loss of 10% or more—Trial running · NCT07743463—Not posted · NCT06939296
Waist circumference, change (cm)—Trial running · NCT07743463—Not posted · NCT06939296

Body weight, % change

ASC30
—Trial running · NCT07743463
VCT220
—Not posted · NCT06939296

Weight loss of 5% or more

ASC30
—Trial running · NCT07743463
VCT220
—Not posted · NCT06939296

Weight loss of 10% or more

ASC30
—Trial running · NCT07743463
VCT220
—Not posted · NCT06939296

Waist circumference, change (cm)

ASC30
—Trial running · NCT07743463
VCT220
—Not posted · NCT06939296
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

VCT220
Phase 2 trial, explicitly named as NCT07011797: primary endpoints met, up to 11.5% weight loss at 36 weeks with CX11 (oral GLP-1 receptor agonist), ongoing weight loss without plateau; gastrointestinal AEs the most common safety finding. NCT07011797 · Phase 2 · design grade: strong · publication or press release
Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18). NCT06939296 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Primary endpoint (mean % body weight change, baseline to week 16): -5.8% to -9.7% across VCT220 dose cohorts vs -1.6% placebo; 9.7% and 9.4% decrease at 160 mg fast/slow titration (p<=0.001) NCT06569355 · Phase 2 · design grade: strong · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ASC30

Weight 7.7% @ 13wk60mg ASC30
percent change · % of baseline
No placebo or comparator arm
NCT07002905 · Phase 2 · sponsor-reported, not registry data
show 2 more results
7% @ 13wk40mg ASC30
NCT07002905 · Phase 2 · sponsor-reported, not registry data
5.4% @ 13wk20mg ASC30
NCT07002905 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · VCT220's landscape